Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients

Hepato-Gastroenterology

Volumn 53, Issue 70, 2006, Pages 634-638

  Romano, Fabrizio ^a   Cesana, Giovanni ^a   Caprotti, Roberto ^a   Bovo, Giorgio ^a   Uggeri, Fabio ^a   Piacentini, Maria Gaia ^b   Crippa, Stefano ^a   Uggeri, Franco ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Gastric cancer; Interteukin 2 (IL 2); Tumor Infiltrating Lymphocytes (TILs)

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERANCE; EOSINOPHIL; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GASTRECTOMY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PREOPERATIVE CARE; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 33748648421     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Allen A, Hogg N: Monocytes and other infiltrating cells in human colorectal tumors identified by monoclonal antibodies. Immunology 1985; 55:289-299.
2. Balch CM, Riley LB, Base YJ, Salomeron MA, Platsoucas CD, Eschenbach AE, Itoh K: Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990; 125:200-205.
3. Lipponen PK, Eskelinen MJ, Janhiainen K, Harjiu E, Terho R: Tumor infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 1993; 29A:69-75.
4. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J: Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 1992; 12:1463-1466.
5. Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, Klein E, Tuason L, Bokowski RM: Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion and proliferation. J Immunother Emph Tumor Immunol 1994; 15:91-104.
6. Wintzer HO, Bohle W, Von Kleist S: Study of the relationship between immunohistochemically demonstrated lymphocytes infiltrating breast carcinomas and patient's survival. J Cancer Res Clin Oncol 1991; 117:163-167.
7. Mihm M, Clemente C, Cascinelli N: Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74:43-47.
8. Naukkarinen A, Syrjanen K: Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinoma, correlation with tumor differentiation. J Pathol 1990; 160:217-222.
9. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491-3494.
10. Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N, Salvadori B, Colnaghi MI, Rilke F: Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997; 3:817-819.
11. Clemente C, Collini P: TIL as a prognostic histopathologic parameter in cutaneous melanoma. Melanoma Res 1993; 3:26-29.
12. Lucin K, Iternicka Z, Jonjic N: Prognostic significance of T-cell infiltrates, expression of beta-2-microglobulin and HLA-DR antigens in breast carcinoma. Pathol Res Pract 1994; 190:1134-1140.
13. Setala LP, Kosma VM, Marin S, et al: Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer 1996; 74:766-772.
14. Golby SJ, Chinyama C, Spencer J: Proliferation of T-cell subsets that contact tumor cells in colorectal cancer. Clin Exp Immunol 2002; 127:85-91.
15. Brivio F, Lissoni P, Tisi E, Erba L, Barni S, Tancini G, Rescaldani R, Alderi G, Nociti V: effects of a preoperative therapy with IL-2 on surgery induced lymphocytopenia in cancer patients. Oncology 1992; 49:215-218.
16. Masotti A, Morandini G, Ortolani R, Fumagalli L: Phase II randomized study of preoperative IL-2 administration in operable NSCLC. Lung Cancer 1998; 20:191-202.
17. Cerea K, Romano F, Ferraro-Bravo A, Motta V, Uggeri F Jr, Brivio F, Fumagalli L, Uggeri F: Phase Ib study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous IL-2 in gastric cancer patients. J Surg Oncol 2001; 78:32-37.
18. Brivio F, Lissoni P, Barni S, Tancini G, Ardizzoia A, Erba L, Alderi G, Nociti V: Effects of a preoperative course of IL-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study. Eur J Surg 1993; 159:43-47.
19. Ropponnen KM, Eskilinen MJ, Lipponen PK, et al: Prognostic value of tumor-infiltrating lyphocytes (TIL) in colorectal cancer. J Pathol 1997; 182.318-324.
20. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M, Carrol L: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35:23-28.
21. Friedl J, Stift A, Paolini P, Roth E, Steger GG, Mader R, Jakesz R, Gnant MF: Tumor antigen pulsed dendritic cells enhance the cytolityc activity of tumor-infiltrating lymphocytes in human hepatocellular cancer. Cancer Biother Radiopharm 2000; 15:477-486.
22. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997; 79:2320-2328.
23. Vesalainen S, Lipponen P, Taljia M, et al: Histological grade, perineural infiltration, tumor-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994; 30:1797-1803.
24. Hakansson L, Adell G, Boeryd B, Sjogren F, Sjodahl R: Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis. Br J Cancer 1997; 75:374-380.
25. Diederichsen AC, Zeuthen J, Christensen PB, et al: Characterisation of tumor infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur J cancer 1999; 35:721-726.
26. Lee WJ, Chang KJ, Lee CS, Chen KM: Selective depression of T-lymphocyte subsets in gastric cancer patients: an implication of immunotherapy. J Surg Oncol 1994; 55:165-169.
27. Fabbri M, Ridolfi R, Maltoni R, et al: Tumor infiltrating lymphocytes and continuous infusion IL-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma. Tumori 2000; 86:46-52.
28. Yoong KF, Adams DH: IL-2 restores CD3-zeta chain expression but fails to generate tumor-specific lytic activity in tumor-infiltrating lymphocytes derived from human colorectal hepatic metastases. Br J Cancer 1998; 77:1072-1081.
29. Sleijfer DT, Janssen RAJ, Buter J, et al: Phase II study of subcutaneous IL-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992; 10:1119-1123.
30. Brivio F, Lissoni P, Fumagalli L, Girlando M, Marsili MT, Nespoli A, Uggeri F: Preoperative IL-2 immunoprophilaxis of cancer recurrence: long-term results of a phase II study in radically operable colorectal cancer. Oncol Rep 1999; 6:1205-1207.
31. Nichols PH, Ramsden CW, Ward U, et al: Perioperative immunotherapy with recombinant IL-2 in patients undergoing surgery for colorectal cancer. Cancer Res 1992; 52:5765-5769.
32. Bennet MW, O'Connell J, O'Sullivan GC, Roche D, Brady C, Kelly J, Collins JK, Shanahan F: expression of Fas ligand by human gastric adenocarcinoma: a potential mechanism of immune escape in stomach cancer. Gut 1999; 44:156-162.
33. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Smith CV, Pecorelli S, Radominska-Pandya A, Cannon MJ, Parham GP: Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 2001; 51:254-261.
34. Schumacher K, Haensch W, Roefzaad W, Schlag PM: Prognostic significance of activated CD8 T cell infiltration within esophageal carcinomas. Cancer Res 2001; 61:3932-3936.
35. Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L: Preoperative IL-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. Oncology 1996; 53:263-268.